Bigelow Elaine, Bever Katherine M, Xu Haiying, Yager Allison, Wu Annie, Taube Janis, Chen Lieping, Jaffee Elizabeth M, Anders Robert A, Zheng Lei
The Sidney Kimmel Comprehensive Cancer Center, The Johns Hopkins University School of Medicine, USA.
J Vis Exp. 2013 Jan 3(71):4059. doi: 10.3791/4059.
B7-H1/PD-L1, a member of the B7 family of immune-regulatory cell-surface proteins, plays an important role in the negative regulation of cell-mediated immune responses through its interaction with its receptor, programmed death-1 (PD-1). Overexpression of B7-H1 by tumor cells has been noted in a number of human cancers, including melanoma, glioblastoma, and carcinomas of the lung, breast, colon, ovary, and renal cells, and has been shown to impair anti-tumor T-cell immunity. Recently, B7-H1 expression by pancreatic adenocarcinoma tissues has been identified as a potential prognostic marker. Additionally, blockade of B7-H1 in a mouse model of pancreatic cancer has been shown to produce an anti-tumor response. These data suggest the importance of B7-H1 as a potential therapeutic target. Anti-B7-H1 blockade antibodies are therefore being tested in clinical trials for multiple human solid tumors including melanoma and cancers of lung, colon, kidney, stomach and pancreas. In order to eventually be able to identify the patients who will benefit from B7-H1 targeting therapies, it is critical to investigate the correlation between expression and localization of B7-H1 and patient response to treatment with B7-H1 blockade antibodies. Examining the expression of B7-H1 in human pancreatic adenocarcinoma tissues through immunohistochemistry will give a better understanding of how this co-inhibitory signaling molecule contributes to the suppression of antitumor immunity in the tumor's microenvironment. The anti-B7-H1 monoclonal antibody (clone 5H1) developed by Chen and coworkers has been shown to produce reliable staining results in cryosections of multiple types of human neoplastic tissues, but staining on paraffin-embedded slides had been a challenge until recently. We have developed the B7-H1 staining protocol for paraffin-embedded slides of pancreatic adenocarcinoma tissues. The B7-H1 staining protocol described here produces consistent membranous and cytoplasmic staining of B7-H1 with little background.
B7-H1/PD-L1是免疫调节性细胞表面蛋白B7家族的一员,通过与程序性死亡受体1(PD-1)相互作用,在细胞介导的免疫反应的负调节中发挥重要作用。肿瘤细胞中B7-H1的过表达已在多种人类癌症中被发现,包括黑色素瘤、胶质母细胞瘤以及肺癌、乳腺癌、结肠癌、卵巢癌和肾细胞癌,并且已证明其会损害抗肿瘤T细胞免疫。最近,胰腺腺癌组织中B7-H1的表达已被确定为一种潜在的预后标志物。此外,在胰腺癌小鼠模型中阻断B7-H1已显示出产生抗肿瘤反应。这些数据表明B7-H1作为潜在治疗靶点的重要性。因此,抗B7-H1阻断抗体正在针对包括黑色素瘤以及肺癌、结肠癌、肾癌、胃癌和胰腺癌在内的多种人类实体瘤进行临床试验。为了最终能够识别出将从B7-H1靶向治疗中获益的患者,研究B7-H1的表达和定位与患者对B7-H1阻断抗体治疗反应之间的相关性至关重要。通过免疫组织化学检查人胰腺腺癌组织中B7-H1的表达,将能更好地了解这种共抑制信号分子如何在肿瘤微环境中促进抗肿瘤免疫的抑制。Chen及其同事开发的抗B7-H1单克隆抗体(克隆5H1)已被证明在多种类型人类肿瘤组织的冰冻切片中能产生可靠的染色结果,但直到最近,在石蜡包埋切片上进行染色仍是一项挑战。我们已经开发出用于胰腺腺癌组织石蜡包埋切片的B7-H1染色方案。这里描述的B7-H1染色方案能产生一致的B7-H1膜性和胞质染色,背景很少。